CRESCENT BIOPHARMA, INC. (CBIO) Operating income 2016–2025
CRESCENT BIOPHARMA, INC. (CBIO) annual operating income history from SEC filings — each fiscal year as reported.
-$152.6MFY2025 · since FY2016: -$31.9M → -$152.6M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$152.6M | -281.2% |
| FY2024 | -$40.0M | -1.9% |
| FY2023 | -$39.3M | +17.1% |
| FY2022 | -$47.4M | +25.3% |
| FY2021 | -$63.4M | -23.2% |
| FY2020 | -$51.5M | +16.1% |
| FY2019 | -$61.4M | -19.2% |
| FY2018 | -$51.5M | -51.8% |
| FY2017 | -$33.9M | -6.3% |
| FY2016 | -$31.9M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More CBIO financial trends
CBIO RevenueCBIO Net incomeCBIO Net marginCBIO Gross profitCBIO Gross marginCBIO Operating marginCBIO Operating cash flowCBIO Free cash flowCBIO Capital expendituresCBIO Return on equityCBIO Stock buybacksCBIO Dividends paidCBIO Total assetsCBIO Total liabilitiesCBIO Shareholders’ equityCBIO overview →